Hims AI Visibility Market Strategy Report - ED Treatment Pills

Answer Capsule

Hims leads the October 2026 ED Treatment Pills benchmark with 60.8% valid recommendation coverage, ahead of Ro at 55.1% by 5.7 percentage points. The brand holds the strongest recommendation position in the category, with a 48.6% top-three rate and a 28.4% rank-one rate, both the highest among tracked brands. Hims also carries the broadest qualified base at 180 valid recommendations and the highest raw mention presence at 92.6%. The clearest weakness is that its rank-one rate remains 4.8 points below its July 2026 level, so the brand has regained shortlist dominance without fully restoring its default-answer position. The clearest opportunity sits in the pricing and multi-brand comparison prompt classes, which the current public benchmark does not yet measure.

Who This Report Is For

This report is for Hims marketing, growth, and brand leadership teams, and for category analysts tracking how AI systems recommend ED treatment providers at the discovery and consideration stage.

Report Card

Executive Summary

Hims holds dominant recommendation power in the ED Treatment Pills category. The October 2026 LLM Authority Index benchmark shows the brand at 60.8% valid recommendation coverage, ahead of Ro at 55.1%, GoodRx Care at 51.0%, and Lemonaid Health at 30.4%. Hims leads on every primary recommendation metric: presence rate at 92.6%, top-three rate at 48.6%, and rank-one rate at 28.4%.

The brand's October profile is strong on both visibility and placement. Of 296 qualified observations, Hims was mentioned in 274, received 180 valid recommendations, appeared in the top three 144 times, and was the single first recommendation 84 times. Its average recommended rank of 2.04 is the best in the category. Sentiment is positive, with 220 positive mentions, 54 neutral mentions, and zero negative mentions, producing a net sentiment score of 0.8029.

The strongest cluster is Brand Recommendation, the only cluster with qualified data in the current public series. Within that cluster, Hims converts broad presence into recommendation placement at a rate no other brand matches. The weakest measured position is the absence of qualified observations in the pricing and value and multi-brand comparison clusters, which means the benchmark cannot yet show how Hims performs when buyers ask cost or head-to-head questions.

The strongest platform signal is AI Overviews, where Hims recorded 87 valid recommendations, a 73.73% valid recommendation coverage rate, and a 38.98% rank-one rate. AI Mode is the second strongest, with 55 valid recommendations and a 67.90% coverage rate. ChatGPT shows the highest coverage rate of any platform at 85.71%, though on a small base of 7 observations.

The clearest platform gap is Perplexity, where Hims recorded a 43.75% valid recommendation coverage rate and a 0.00% rank-one rate across 16 observations. Copilot is the second gap, with a 26.92% coverage rate and an average recommended rank of 4.71, the weakest placement profile of any platform where Hims receives rank credit.

Three critical or high-severity factual inconsistencies were detected for Hims across four AI platforms. These conflicts concern Zepbound availability and relative pricing against Ro and BlueChew, and they represent a distinct risk to how AI systems frame the brand at the comparison and pricing stages.

What Hims Is Winning

Questions This Section Answers

• Which recommendation metrics does Hims lead in the ED Treatment Pills category?
• How does Hims' rank-one rate compare with Ro's despite similar coverage?
• Which platforms produce Hims' strongest recommendation signal?

Hims holds the category lead in valid recommendation coverage at 60.8%, ahead of Ro by 5.7 percentage points. The brand also leads on raw mention presence at 92.6%, meaning it appears in nearly every qualified AI response in the category.

The brand's placement profile is the strongest in the benchmark. Hims recorded 144 top-three recommendations and 84 rank-one recommendations, both the highest counts among tracked brands. Its rank-one rate of 28.4% is more than double Ro's 9.8%, even though the two brands hold relatively close coverage. Its average recommended rank of 2.04 is the best in the category.

Hims shows no negative framing in the October data. Across 274 mentions, the brand recorded 220 positive and 54 neutral classifications, with zero negative mentions. This is the cleanest sentiment profile among the top three brands by coverage.

The brand's strongest platform is AI Overviews, where it recorded 87 valid recommendations and a 73.73% coverage rate. AI Mode is the second strongest, with 55 valid recommendations and a 67.90% coverage rate. ChatGPT produced the highest coverage rate at 85.71%, though on a small base.

Where Hims Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why is Hims being shortlisted without always being named first?
• Which platforms never place Hims in the first position?
• How is GoodRx Care converting visibility into rank-one placements against Hims?

The clearest gap is rank-one restoration. Hims' October rank-one rate of 28.4% is 4.8 points below its July 2026 level of 33.2%. The brand recovered significant ground against September, rising 14.2 points in coverage from 46.6% to 60.8%, but it has not fully restored its default-answer position. This means Hims is consistently shortlisted without always being the first recommendation.

Perplexity is the weakest platform for first-position placement. Across 16 observations, Hims recorded a 43.75% valid recommendation coverage rate but a 0.00% rank-one rate. The brand is present and recommended on Perplexity, but it is not being named first. Copilot shows a related pattern: a 26.92% coverage rate and an average recommended rank of 4.71, the weakest placement profile of any platform where Hims receives rank credit.

GoodRx Care is the clearest displacement risk. The brand rose 7.0 points from the July baseline to 51.0% coverage, and its rank-one rate rose 11.9 points to 15.9%. GoodRx Care is now converting broad visibility into first-position placements at a rate approaching the leaders. Where GoodRx Care wins rank one, Hims is the most likely brand being displaced.

The benchmark does not yet measure pricing and value or multi-brand comparison prompts. This is a structural gap rather than a performance gap, but it means Hims' position on cost and head-to-head questions is not visible in the current public data.

Biggest Opportunity

The clearest opportunity is to restore Hims' rank-one rate to its July level and defend first-position placement against GoodRx Care. Hims already holds the broadest qualified base in the category at 180 valid recommendations and the highest presence rate at 92.6%. The gap is not visibility; it is the conversion of that visibility into the single first recommendation.

This opportunity is concentrated in two places. On Perplexity, Hims receives recommendation credit but never rank one. On Copilot, the brand's average recommended rank of 4.71 suggests it is being listed below stronger options. Closing these two platform gaps would lift the brand's overall rank-one rate without requiring new presence.

The second opportunity is to prepare for the pricing and multi-brand comparison clusters. These prompt classes are defined in the benchmark but carry no qualified observations in the current public series. When they are measured, Hims will need a clear, consistent pricing and comparison narrative in the public evidence layer to defend its position.

Competitive Landscape

Questions This Section Answers

• How does Hims' top-three and rank-one performance compare with Ro and GoodRx Care?
• Which brand has the best average recommended rank in the ED Treatment Pills category?

Hims holds the strongest recommendation-stage position in the ED Treatment Pills category, leading on coverage, top-three rate, and rank-one rate. Ro is the closest challenger on coverage, while GoodRx Care is the strongest mover on placement.

Average recommended rank covers rank-eligible recommendations only.

Hims leads the table on top-three rate and rank-one rate, and holds the best average recommended rank at 2.04. Ro is the closest challenger on top-three rate but trails sharply on rank-one rate, at 9.80% versus 28.38%. GoodRx Care sits third on top-three rate but second on rank-one rate, which shows it is converting fewer shortlist appearances into more first-position placements than Ro.

AI Response Inconsistency Alerts

Questions This Section Answers

• What factual inconsistencies did AI platforms produce about Hims?
• Which platforms disagreed about Hims' pricing relative to Ro and BlueChew?
• What conflicting claims exist about Zepbound availability through Hims?

Three critical or high-severity factual inconsistencies were detected for Hims across four AI platforms: ChatGPT, Gemini, AI Overviews, and Perplexity.

The first conflict is critical and concerns the availability of Zepbound. When asked "How much is zepbound through Hims?", AI Overviews stated that Hims offers branded Zepbound (tirzepatide) for a monthly price plus membership, citing the Hims weight loss page and a Hims product page. Gemini stated that Hims does not offer brand-name Zepbound or Mounjaro. These two claims cannot both be true. The conflicting responses were produced by AI Overviews and Gemini, and the AI Overviews answer cited hims.com pages alongside a news source reporting that Hims added Eli Lilly's Zepbound.

The second conflict is high severity and concerns relative price against Ro. When asked "Is Hims or Ro more expensive?", ChatGPT stated that Ro is generally cheaper than Hims, especially long term, citing the Hims homepage and Ro's weight loss pricing page. Perplexity stated that Hims is typically a bit cheaper than Ro for similar ED treatments, citing Medical News Today, a cost comparison page, and Ro's own comparison guide. The two platforms reached opposite conclusions on the same question.

The third conflict is high severity and concerns the overall cheaper option against BlueChew. When asked "Is BlueChew or Hims cheaper?", ChatGPT stated that Hims is generally cheaper, especially for standard sildenafil or tadalafil, citing BlueChew's tadalafil page. Perplexity stated that BlueChew is generally cheaper per dose, with plans often starting around a lower monthly figure, citing Medical News Today and a comparison page. The flagged sources on the Perplexity side included BlueChew's own comparison content, which may help explain why that platform framed BlueChew as the lower-cost option.

Prompt Evidence

AI Overviews / Brand Recommendation Prompt: "What is the best online pharmacy for tirzepatide?" Result: Hims was recommended in the top three, consistent with its strongest platform profile and its 73.73% coverage rate on AI Overviews.

Perplexity / Brand Recommendation Prompt: "Is Hims or Ro more expensive?" Result: Perplexity stated that Hims is typically a bit cheaper than Ro for similar ED treatments, while ChatGPT reached the opposite conclusion on the same question, producing a pricing conflict.

Copilot / Brand Recommendation Prompt: "Which online doctors are legit?" Result: Hims received recommendation credit but at an average recommended rank of 4.71 on Copilot, the weakest placement profile of any platform where the brand receives rank credit.

Gemini / Brand Recommendation Prompt: "How much is zepbound through Hims?" Result: Gemini stated that Hims does not offer brand-name Zepbound, directly conflicting with the AI Overviews answer that Hims does offer it.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map every qualified prompt where Hims is mentioned but not recommended first, with priority on Perplexity and Copilot, where rank-one placement is weakest.

Phase 2: Recommendation Readiness Plan Identify which prompt themes route first position away from Hims and which competitor, most likely GoodRx Care, is taking that position.

Phase 3: Owned Answer Layer Buildout Build clear, consistent owned pages on Zepbound availability and pricing so AI systems retrieve one accurate answer instead of conflicting ones.

Phase 4: Citation / Authority Layer Development Strengthen the third-party source pages that AI systems cite for Hims pricing and comparison questions, since the current conflicts trace partly to comparison and publisher sources.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track rank-one rate, Perplexity and Copilot placement, and pricing-cluster coverage month over month as the benchmark adds new prompt classes.

Why This Matters

Hims leads the category on coverage, but coverage alone does not decide the buyer's shortlist. A buyer who asks an AI system which ED treatment provider to choose sees a ranked answer, and the brand named first carries an advantage that a brand named fourth does not. Hims holds the strongest overall position, yet its rank-one rate is below its own July level and two platforms never place it first.

The next move is targeted correction of the prompt, page, and citation layers. Hims needs consistent owned answers on availability and pricing, stronger third-party sources for comparison questions, and focused work on the platforms where it is recommended but not named first. That is how a category leader converts presence into the default answer.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Hims in October 2026, the score is (220 × 1 + 54 × 0 + 0 × -1) / 274 = 0.8029.

This matters because unclassified mention counts are misleading. A brand can appear in hundreds of AI responses and still lose the buyer if those appearances are neutral references, cautionary notes, or competitor comparisons. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal, and counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because it separates genuine recommendation strength from simple presence.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Hims in the ED Treatment Pills category, drawing on the October 2026 LLM Authority Index AI Market Discovery Index and the associated company-level metrics.
2. The reporting month is October 2026, with July 2026 as the series baseline and August and September 2026 used for month-over-month interpretation.
3. Six AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode. All six registered qualified observations in October 2026.
4. The October run began with 800 source prompt-surface observations and 658 unique questions. Of those, 547 were relevant and 253 were irrelevant, producing 296 qualified benchmark observations.
5. The competitor universe contains ten tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, plushcare, BlueChew, Rex MD, Blink Health, K Health, and Optum.
6. One public high-intent cluster carried qualified data in October 2026: Brand Recommendation, covering discovery and consideration prompts. Pricing and value and multi-brand comparison clusters are defined but carried no qualified observations in the current public series.
7. Stage 0 extraction captured the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources for each observation.
8. A mention is counted when a tracked brand appears in a qualified AI response, regardless of recommendation status.
9. A valid recommendation is counted when a brand appears in a valid recommendation position, as marked by the dataset. Neutral, cautionary, comparison-anchor, and listed-only mentions are not counted as valid recommendations.
10. Brand-level percentages use the 296 qualified observations as the public denominator, not the full 800-prompt raw collection.
11. Average recommended rank covers rank-eligible recommendations only. A brand with no rank-eligible recommendations is shown with no average rank.
12. The benchmark records change; it does not establish why change occurred. Source presence in AI responses is evidence about the information environment and is not automatically proof that a source caused a recommendation.

See How AI Is Recommending Your Brand

The public benchmark shows where Hims leads and where it is recommended without being named first. A company-level AI visibility audit maps the prompt, platform, competitor, ranking, sentiment, and source patterns behind those numbers into a prioritized plan, so the next question becomes which prompts to win and what evidence will move the answer.